Search Results - Ardizzoni, Andrea

Refine Results
  1. 1
    Is the door open to further investigation with antiangiogenesis in SCLC?

    Is the door open to further investigation with antiangiogenesis in SCLC? by Tiseo, Marcello, Boni, Luca, Ardizzoni, Andrea

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  2. 2
    It Takes Two to Tango: How a Dysregulation of the Innate Immunity, Coupled With Candida Virulence, Triggers VVC Onset

    It Takes Two to Tango: How a Dysregulation of the Innate Immunity, Coupled With Candida Virulence, Triggers VVC Onset by Ardizzoni, Andrea, Wheeler, Robert T., Pericolini, Eva

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  3. 3
    Systemic adjuvant therapies in renal cell carcinoma

    Systemic adjuvant therapies in renal cell carcinoma by Buti, Sebastiano, Bersanelli, Melissa, Donini, Maddalena, Ardizzoni, Andrea

    Published 2012
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  4. 4
    Chemotherapy treatment in malignant pleural mesothelioma: a difficult history

    Chemotherapy treatment in malignant pleural mesothelioma: a difficult history by Cinausero, Marika, Rihawi, Karim, Sperandi, Francesca, Melotti, Barbara, Ardizzoni, Andrea

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  5. 5
    Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients’ care

    Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients’ care by Massari, Francesco, Mollica, Veronica, Salvagni, Stefania, Tognetto, Michele, Ardizzoni, Andrea

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  6. 6
    Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment

    Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment by Raschi, Emanuel, Fusaroli, Michele, Ardizzoni, Andrea, Poluzzi, Elisabetta, De Ponti, Fabrizio

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  7. 7
    Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System

    Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System by Raschi, Emanuel, Fusaroli, Michele, Ardizzoni, Andrea, Poluzzi, Elisabetta, De Ponti, Fabrizio

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  8. 8
    Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase

    Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporti... by Gatti, Milo, Raschi, Emanuel, Moretti, Ugo, Ardizzoni, Andrea, Poluzzi, Elisabetta, Diemberger, Igor

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  9. 9
    Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma

    Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma by Comito, Francesca, Pagani, Rachele, Grilli, Giada, Sperandi, Francesca, Ardizzoni, Andrea, Melotti, Barbara

    Published 2022
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  10. 10
    Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance

    Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance by Raschi, Emanuel, Gatti, Milo, Gelsomino, Francesco, Ardizzoni, Andrea, Poluzzi, Elisabetta, De Ponti, Fabrizio

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  11. 11
    Anti-insulin-like growth factor-I activity of a novel polysulphonated distamycin A derivative in human lung cancer cell lines

    Anti-insulin-like growth factor-I activity of a novel polysulphonated distamycin A derivative in human lung cancer cell lines by de Cupis, Alessandra, Ciomei, Marina, Pirani, Paolo, Ferrera, Alessandra, Ardizzoni, Andrea, Enrico Favoni, Roberto

    Published 1997
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  12. 12
    Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence

    Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence by Rihawi, Karim, Gelsomino, Francesco, Sperandi, Francesca, Melotti, Barbara, Fiorentino, Michelangelo, Casolari, Laura, Ardizzoni, Andrea

    Published 2017
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  13. 13
    Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer

    Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer by Parisi, Claudia, Lamberti, Giuseppe, Zompatori, Maurizio, Gelsomino, Francesco, Salvagni, Stefania, Sperandi, Francesca, Ardizzoni, Andrea

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  14. 14
    The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia

    The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia by Gatti, Milo, Raschi, Emanuel, Poluzzi, Elisabetta, Martignani, Cristian, Salvagni, Stefania, Ardizzoni, Andrea, Diemberger, Igor

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  15. 15
    Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers

    Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers by Giunchi, Francesca, Massari, Francesco, Altimari, Annalisa, Gruppioni, Elisa, Nobili, Elisabetta, Fiorentino, Michelangelo, Ardizzoni, Andrea

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  16. 16
    Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis

    Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Revi... by Di Federico, Alessandro, De Giglio, Andrea, Parisi, Claudia, Gelsomino, Francesco, Boni, Luca, Ardizzoni, Andrea

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  17. 17
    Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System

    Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System by Raschi, Emanuel, Antonazzo, Ippazio Cosimo, La Placa, Michelangelo, Ardizzoni, Andrea, Poluzzi, Elisabetta, De Ponti, Fabrizio

    Published 2019
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  18. 18
    Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System

    Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting S... by Sisi, Monia, Fusaroli, Michele, De Giglio, Andrea, Facchinetti, Francesco, Ardizzoni, Andrea, Raschi, Emanuel, Gelsomino, Francesco

    Published 2022
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  19. 19
    Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology

    Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology by Gridelli, Cesare, Ardizzoni, Andrea, Barberis, Massimo, Cappuzzo, Federico, Casaluce, Francesca, Danesi, Romano, Troncone, Giancarlo, De Marinis, Filippo

    Published 2017
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  20. 20
    In vitro effects of commercial mouthwashes on several virulence traits of Candida albicans, viridans streptococci and Enterococcus faecalis colonizing the oral cavity

    In vitro effects of commercial mouthwashes on several virulence traits of Candida albicans, viridans streptococci and Enterococcus faecalis colonizing the oral cavity by Ardizzoni, Andrea, Pericolini, Eva, Paulone, Simona, Orsi, Carlotta Francesca, Castagnoli, Anna, Oliva, Ilaria, Strozzi, Elena, Blasi, Elisabetta

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:

Search Tools: